Jeffrey Nau named CEO of Aviceda Therapeutics

(Image credit: ©ASDF/AdobeStock)

Aviceda Therapeutics recently appointed Jeffrey Nau, PhD, MMS, as chief executive officer. Nau comes to Aviceda with more than 20 years of experience leading and expanding biotechnology and pharmaceutical companies.¹

In his most recent role as chief operating officer of Kalaris Therapeutics, Nau helped the company shape its operation and strategic vision while leading the company through a merger with Allovir, Inc. Nau also served as chief executive officer of Oyster Point, where he led company through its initial public offering in 2019, helped secured more than $300 million in funding, and oversaw Oyster Point’s 2023 acquisition by Viatris.

Nau has been at the frontline, helping to lead the launch of numerous drugs for the treatments of dry eye disease, geographic atrophy (GA), and diabetic macular edema (DME).

Under his leadership, Oyster Point launched Tyrvaya – the first FDA-approved nasal spray for the treatment of dry eye disease; the company also expanded its pipeline, developing an investigational Enriched Tear Film Gene Therapy program. While at Genentech (Roche), Nau had a hand in developing and launching Lucentis – a treatment indicated for wet age-related macular degeneration (AMD), DME, and other blinding conditions. As part of the team at Ophthotech (now Iveric Bio), he was part of the early development of Izervay, a treatment for GA.

“I am honored to join Aviceda and look forward to working with this talented team to advance our pipeline, forge strategic partnerships, and deliver breakthrough therapies that have the potential to change the treatment of geographic atrophy and other serious diseases,” Nau said in a press release.

Nau received a PhD in Public Health and Epidemiology from Walden University, a Master of Medical Science from Drexel University College of Medicine and a Bachelor of Science in Biology from Stony Brook University.

References:

1. Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation. BioSpace. Published April 2025. Accessed April 11, 2025. https://www.biospace.com/press-releases/aviceda-therapeutics-appoints-industry-veteran-dr-jeffrey-nau-as-chief-executive-officer-to-lead-next-phase-of-growth-and-innovation